Veradermics to Present Phase 3 Hair Loss Trial Results

Veradermics, Incorporated (NYSE:MANE) will hold an investor call and live webcast on October 19, 2026, at 8:00 a.m. ET to present initial Phase 3 results for its lead drug candidate, VDPHL01. The Study '304' trial evaluated the extended-release oral minoxidil tablet in 536 men with mild-to-moderate pattern hair loss over a randomized, double-blind, placebo-controlled study period.

The trial outcome represents a key milestone for the biopharmaceutical firm, which is developing non-hormonal oral treatments for hair restoration. Pattern hair loss impacts roughly 80 million individuals in the United States, and no new prescription treatments have received regulatory approval in nearly three decades. If approved, VDPHL01 could become the first oral non-hormonal treatment for male and female pattern hair loss.

Investors and clinical observers will evaluate the co-primary endpoint data from Month 6 during the upcoming conference call. The broader clinical program includes two additional Phase 2/3 trials across more than 1,600 total subjects, aiming to support potential regulatory submission to the U.S. Food and Drug Administration. Ahead of the presentation, company shares traded down 5.43% to $108.80.